Position in XGN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,480,980
-$1,437,596 QoQ
Shares Held
493,660
+2.8% QoQ
Ownership
2.04%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026KENNEDY CAPITAL MANAGEMENT LLC holds $48,575,766 across 13 Diagnostics & Research names. XGN ranks #10 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PSNL |
Personalis, Inc.
|
2,183,572 | $13,909,353 | |
| 2 | CRL |
Charles River Laboratories International, Inc.
|
43,634 | $7,526,865 | |
| 3 | TMO |
Thermo Fisher Scientific Inc.
|
14,073 | $6,917,301 | |
| 4 | A |
Agilent Technologies, Inc.
|
41,202 | $4,696,203 | |
| 5 | ADPT |
Adaptive Biotechnologies Corp
|
931,522 | $3,232,381 | |
| 6 | DHR |
Danaher Corp /De/
|
14,638 | $2,775,364 | |
| 7 | WGS |
GeneDx Holdings Corp.
|
34,562 | $2,219,571 | |
| 8 | VCYT |
Veracyte, Inc.
|
54,320 | $1,749,647 |
All Filings in XGN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,480,980 | 493,660 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $2,918,576 | 480,029 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $6,064,809 | 551,848 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $2,168,832 | 310,721 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $1,059,599 | 295,153 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $756,339 | 184,473 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $523,918 | 169,553 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $139,253 | 76,513 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||